Abstract: A sustained-release pharmaceutical formulation containing mizolastine, a core formed of a sustained-release table containing mizolastine combined with a fatty matrix and an organic acid, the tablet being coated.

Abstract: The present invention relates to a process for the preparation of a compound of general formula (I), ##STR1## wherein R.sup.1 represents a hydrogen atom or an alkyl group of 1-6 carbon atoms, and their salts, wherein the compound of formula (II): ##STR2## is reacted with a compound of formula (III): ##STR3## wherein R represents an alkyl group of 1-4 carbon atoms and R.sup.1 is the same as defined above, by heating their neutral pH mixtures at the boiling temperature of the mixture, and the resulting compound of general formula (IV): ##STR4## wherein R and R.sup.1 are the same as defined above, is cyclized into the compound of general formula (I) by further elevating the temperature of the neutral mixture, and if desired, the compounds of general formula (I) are transformed into their salts, or the compounds of general formula (I) are liberated from their salts.

Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

Abstract: Disclosed are: aqueous parenteral formulations for the treatment of cancer tumors comprising 1,2,4-benzotriazine 1,4-dioxides in a citrate buffer; and method of cancer tumor treatment.

Abstract: Pharmaceutical tablet which consists of:a) a first layer having the property of swelling considerably and quickly on contact with aqueous biological fluids, the first layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers, andb) a second layer adjacent to the first layer being formulated with hydrophilic polymers and with other auxiliary substances in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period.

Abstract: Compounds corresponding to the general formula (I) ##STR1## in which R.sub.1 represents a hydrogen atom, a (C.sub.1 -C.sub.6)alkyl group or a phenyl(C.sub.1 -C.sub.4)alkyl group, R.sub.2 represents a hydrogen atom or a (C.sub.1 -C.sub.6)alkyl group and R.sub.3, R.sub.4 and R.sub.5 each represent, independently of one another, a hydrogen or halogen atom or a trifluoromethyl, cyano, hydroxyl, (C.sub.1 -C.sub.6)alkyl or (C.sub.1 -C.sub.6)alkoxy group. Application in therapeutics.

Abstract: Compounds derived from 3-(benzofuran-5-yl) oxazolidin-2-one, of general formula (I) ##STR1## in which: R.sub.1 represents a phenyl group, a phenylmethyl group, an alkyl group or a fluoroalkyl group, and R.sub.2 represents a hydrogen atom or a methyl group. Application in therapeutics.

Abstract: The invention relates to the use of a specific 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of the sleep apnea syndrome.

Abstract: The invention concerns the use of mizolastine and the pharmaceutically acceptable salts thereof for making a medicine for treating inflammatory diseases or inflammatory constituents of some other diseases related to the 5-lipoxygenase route.

Abstract: The invention relates to compounds of the formula ##STR1## in which: Y is --CH-- or --N--;R.sub.1 is a halogen or a CF.sub.3, (C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxy group;R.sub.2 and R.sub.3 are each hydrogen or a (C.sub.1 -C.sub.3)alkyl;n is 0 or 1; andPh.sub.1 and Ph.sub.2 are each independently an unsubstituted, monosubstituted or polysubstituted phenyl group;to a process for their preparation and to the pharmaceutical compositions containing them.These compounds have neurotrophic and neuroprotective activity.

Abstract: The invention concerns a method for preparing an optically active alcohol of formula (I) in which the carbon atom indicated by the symbol * can have the configuration (R) or (S) and X represents a non-substituted amino group or a mono- or di-(C.sub.1 -C.sub.4)alkylamino group optionally salified from corresponding ketones by catalytic hydrogenation in the presence of a rhodium complex.

Abstract: The invention relates to a method for the preparation of 1-[2-(2-naphthyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyri dine and its pharmaceutically acceptable salts by reacting 2-(2-bromoethyl)naphthalene with 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or one of its salts, and to a universal method for the preparation of the same product and its salts by the reduction of naphthylacetic acid, treatment of the resulting 2-naphthylethanol with hydrobromic acid and treatment of the 2-(2-bromoethyl)naphthalene with 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or one of its salts.

Abstract: The invention relates compounds of formula ##STR1## in which R.sub.1 to R.sub.9, R.sub.16 and R.sub.17 are as defined in claim 1.These compounds are pharmacologically active.

Abstract: The invention relates to compounds with formula (I), a process for their preparation and pharmaceutical compositions containing them.

Abstract: The present invention relates to a process for the preparation of 2-thienylethylamine derivatives of general formula: ##STR1## as well as their acid addition salts, in which R represents a halogen atom and R.sub.1 represents a C.sub.1 -C.sub.4 alkyl group, characterized in that a thienylglycidic derivative of general formula: ##STR2## in which M represents an alkali metal atom or a fraction of an alkaline-earth metal atom, is reacted with a phenylglycine ester, optionally in the form of a strong acid salt, of general formula: ##STR3## in which R and R.sub.1 have the same meaning as above, in the presence of an alkali metal borchydride of general formula:X--Y IVin which X represents an alkali metal atom and Y represents a group of formula:--BH.sub.3 CN or --BH.sub.(4-w) Z.sub.win which Z represents a carboxylic acid residue and optionally in the presence of a C.sub.1 -C.sub.

Abstract: Compounds of general formula (I) ##STR1## in which the variables are as defined in the specification, their preparation and their application in therapeutics.

Abstract: A pharmaceutical composition, comprising a lipophilic phase and, as active principle, at least one compound selected froman optically active isomer or a racemate of amisulpride;an optically active isomer or a racemate of a pharmaceutically acceptable acid addition salt of amisulpride;an optically active isomer or a racemate of a quaternary ammonium salt of amisulpride; andan optically active isomer or a racemate of an oxide of amisulpride.

Abstract: In accordance with the present invention there is provided a method of treating a mammal having a solid tumor, the method comprising:a) administering to the mammal an effective amount of 3-amino-1,2,4-benzotriazine 1,4-dioxide;b) administering to the mammal an effective amount of paclitaxel; andc) administering to the mammal an effective amount of a platinum complex.The method provides unexpected synergistic efficacy. The invention further provides a kit for treatment of a mammalian tumor comprising 3-amino-1,2,-benzotriazine 1,4-dioxide, paclitaxel and a platinum complex.

Abstract: Compounds of formula (I), wherein A is a hydrogen atom or a hydroxyl group; B is a hydrogen atom or a C.sub.1-8 alkyl, C.sub.1-8 alkenyl, C.sub.1-8 fluoroalkyl or C.sub.1-8 perfluoroalkyl group; each of R.sub.1, R.sub.2 and R.sub.5, which are the same or different, is a hydrogen atom, a halogen such as chlorine, bromine or fluorine, a C.sub.1-8 alkyl, C.sub.1-8 alkenyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkenyl, C.sub.6, C.sub.10 or C.sub.14 aryl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 hydroxyalkyl, C.sub.1-6 alkoxyalkyl, C.sub.1-6 alkoxy, C.sub.1-8 fluoroalkyl or C.sub.1-8 perfluoroalkyl group, or R.sub.1 and R.sub.2 taken together form a C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkenyl or C.sub.6, C.sub.10 or C.sub.14 aryl ring, except for compounds in which R.sub.1 and R.sub.2 are both hydrogen; each of R.sub.3 and R.sub.4, which are the same or different, is a hydrogen atom or a C.sub.1-8 alkyl, C.sub.1-8 alkenyl, C.sub.3-8 cycloalkyl or C.sub.3-8 cycloalkenyl group, or R.sub.3 and R.sub.

Abstract: Compounds of general formula (I) ##STR1## in which: A represents either a hydrogen atom, a hydroxyl, a C.sub.1-6 hydroxyalkyl group, a thiol, a C.sub.1-6 alkylsulphanyl group, an amino group, a C.sub.1-6 alkylamino group, a di(C.sub.1-6 alkyl)amino group, a C.sub.1-6 alkylhydroxylamine group, a C.sub.1-6 alkoxy group, a hydroxylamine group, an N,O-di(C.sub.1-6 alkyl)hydroxylamine group, an azido or a halogen such as fluorine, chlorine or bromine, B represents a hydrogen atom, a linear or branched C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.1-6 fluoroalkyl group, a C.sub.1-2 perfluoroalkyl group, a C.sub.1-6 alkoxy group, a phenyl group or an oxo group, X represents an oxygen or sulphur atom.Application in therapeutics.